About: Pralatrexate     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Pralatrexate
rdfs:subClassOf
Concept_In_Subset
Semantic_Type
  • Organic Chemical
  • Pharmacologic Substance
Preferred_Name
  • Pralatrexate
UMLS_CUI
  • C0879404
CAS_Registry
  • 146464-95-1
In_Clinical_Trial_For
  • Advanced Solid Tumors; Recurrent or Refractory Aggressive Non-Hodgkins Lymphoma; Hodgkins Lymphoma; Advanced Non-Small Cell Lung Cancer.
FDA_UNII_Code
  • A8Q8I19Q20
Contributing_Source
  • FDA
ALT_DEFINITION
  • A drug used in the treatment of peripheral T-cell lymphoma (a fast-growing form of non-Hodgkin lymphoma). It is also being studied in the treatment of other types of cancer. Pralatrexate may block the growth of cancer cells and cause them to die. It is a type of dihydrofolate reductase (DHFR) inhibitor.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 37828
PDQ_Closed_Trial_Search_ID
  • 37828
Legacy_Concept_Name
  • _10-Propargyl-10-Deazaaminopterin
FULL_SYN
  • PRALATREXATEPTFDAA8Q8I19Q20
  • N-(4-{1-[(2,4-Diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic AcidSNNCI
  • PralatrexatePTNCI
  • (2S)-2-[[4-[(1RS)-1-[(2, 4-Diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic AcidSNNCI
  • 10-propargyl-10-deazaaminopterinPTNCI-GLOSSCDR0000044880
  • PDXABNCI
  • pralatrexatePTNCI-GLOSSCDR0000657510
  • FOLOTYNPTNCI-GLOSSCDR0000657511
  • FolotynBRNCI
  • 10-Propargyl-10-DeazaaminopterinSNNCI
DEFINITION
  • A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.NCI
code
  • C2250
sameAs
http://linked.open...y/mesh/hasConcept
is someValuesFrom of
is sameAs of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 18 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software